Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis

被引：0
|
作者：
Kaur, M. [1 ]
Merola, J. [2 ]
Tatulych, S. [3 ]
Mamolo, C. [3 ]
Lan, S. [3 ]
机构：
[1] Pfizer, Collegeville, PA USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dermatol, Boston, MA USA
[3] Pfizer, Groton, CT USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
psoriasis; nails; tofacitinib;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P157
引用
收藏
页码：81 / 81
页数：1
相关论文
共 50 条
  • [21] Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Data from a Phase 3 Trial
    Ghislain, Pierre-Dominique
    Conrad, Curdin
    Dutronc, Yves
    Henneges, Carsten
    Calderon, David Sandoval
    Vincent, Myriam
    Ghys, Liesbet
    de Gruijter, Jolien
    van de Kerkhof, Peter C. M.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [22] Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL
    Gold, Linda Stein
    Bagel, Jerry
    Lebwohl, Mark
    Jackson, J. Mark
    Chen, Rongdean
    Goncalves, Joana
    Levi, Eugenia
    Duffin, Kristina Collis
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (02) : 221 - 228
  • [23] Pooled safety analysis from two phase III studies of secukinumab in paediatric patients with moderate-to-severe plaque psoriasis up to week 52
    Sticherling, M.
    Nikkels, A. F.
    Hamza, A. M.
    Kwong, P.
    Ortmann, C. -E.
    Papanastasiou, P.
    Forrer, P.
    Keefe, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E39 - E40
  • [24] Ixekizumab is superior to placebo for the treatment of nail, scalp, and palmoplantar psoriasis in pediatric patients with moderate to severe plaque psoriasis
    Paller, Amy S.
    Magarinos, Gabriel Alejandro
    Pinter, Andreas
    Cather, Jennifer
    Keller, Stuart
    Capriles, Claudia Rodriguez
    Gallo, Gaia
    Edson-Heredia, Emily
    Li, Lingnan
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB20 - AB20
  • [25] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Elewski, Boni
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
  • [26] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Merola, Joseph F.
    Elewski, Boni
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
  • [27] SUSTAINED AND IMPROVED EFFICACY OF TILDRAKIZUMAB FROM WEEK 28 TO WEEK 52 IN TREATING MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Elewski, Boni
    Menter, Alan
    Crowley, Jeffrey
    Tyring, Stephen
    Zhao, Yang
    Lowry, Simon
    Rozzo, Stephen
    Mendelsohn, Alan
    Parno, Jeffrey
    Gordon, Kenneth
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 31 - 31
  • [28] Efficacy and safety of oral tofacitinib in North American patients with moderate to severe plaque psoriasis: Pooled analyses of data from randomized phase 3 studies
    Korman, Neil J.
    King, Brett
    Wolk, Robert
    Tan, Huaming
    Kaur, Mandeep
    Robertson, Debbie
    Langley, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB247 - AB247
  • [29] EFFICACY AND SAFETY OF APREMILAST AND SWITCH FROM ETANERCEPT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: 52-WEEK RESULTS FROM THE LIBERATE STUDY
    Reich, K.
    Soung, J.
    Gooderham, M.
    Zhang, Z.
    Nograles, K.
    Day, R. M.
    Ferris, L.
    Goodfield, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 758 - 759
  • [30] 52-WEEK EFFICACY AND SAFETY OF APREMILAST AND SWITCH FROM ETANERCEPT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: RESULTS FROM THE LIBERATE STUDY
    Reich, K.
    Soung, J.
    Gooderham, M.
    Zhang, Z.
    Nograles, K.
    Day, R. M.
    Ferris, L.
    Goodfield, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 349 - 349
12345